Kinevant Sciences
Kinevant Sciences is a clinical-stage biopharmaceutical company founded in 2019 and based in New York, dedicated to developing treatments for rare autoimmune diseases with significant unmet medical needs. It operates within the Roivant Vant ecosystem.
- Company typePrivate
- Founded2019
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Kinevant Sciences does
Kinevant Sciences is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in New York, United States. The company is dedicated to developing treatments for rare autoimmune diseases with significant unmet medical needs, operating within the Roivant Sciences ecosystem as one of its "Vants" — a structural model designed to create agile, focused subsidiaries with aligned incentives for efficient drug development and rigorous capital allocation.
The company's core focus is the discovery and development of therapeutic candidates for rare autoimmune conditions, though specific drug candidates, mechanisms of action, target indications, or clinical trial programs are not disclosed in the available data. As a clinical-stage entity, Kinevant does not yet have commercialized products, and its underlying technology and scientific approach are not explicitly described in the input material. The company leverages the Roivant parent's technology-enabled discovery, development, and commercialization infrastructure.
Kinevant operates with a very small team of 1-10 employees, consistent with an early-stage, asset-focused development model typical of clinical-stage biotech subsidiaries. Its business model is pre-commercial, with no disclosed revenue, pricing, or customer base. Economics are expected to depend on advancing therapeutic candidates through regulatory milestones, potentially benefiting from orphan drug exclusivity given the rare disease focus. Funding flows through the Roivant parent and its capital allocation framework rather than through independently disclosed rounds.
Kinevant Sciences firmographics
Firmographics- Name
- Kinevant Sciences
- Website
- https://kinevant.com
- Company type
- Private
- Founded year
- 2019
- Headcount range
- 1–10 employees
- Short description
- Kinevant Sciences is a clinical-stage biopharmaceutical company founded in 2019 and based in New York, dedicated to developing treatments for rare autoimmune diseases with significant unmet medical needs. It operates within the Roivant Vant ecosystem.
- Ownership category
- akta.pro rank
Kinevant Sciences industry classification
Industry- Product category
- Rare Disease Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Kinevant Sciences is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
Kinevant Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Kinevant Sciences product offering
Product offeringCore offering
Kinevant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for rare autoimmune diseases with significant unmet medical needs. As a subsidiary "Vant" under Roivant Sciences, it focuses its pipeline on rare autoimmune indications, leveraging Roivant's technology-enabled discovery, development, and commercialization capabilities. The company is currently pre-commercial and operates with 1-10 employees.
Differentiator
Problem solved
Functional benefit
Companies that use Kinevant Sciences
Customer profileIdeal customer profiles2 records
Kinevant Sciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Kinevant Sciences partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights3 records
Kinevant Sciences competitors and assessment
Company assessmentEmerging players
- AnaptysBio: Clinical-stage biotechnology company developing inflammation and autoimmune therapeutics, including IL-36 and checkpoint agonist antibodies. Comparable in therapeutic focus area and clinical-stage development profile.
- Viridian Therapeutics: Clinical-stage biotechnology company developing therapeutics for autoimmune diseases, particularly in rare endocrinology and ophthalmology. Comparable in targeting rare autoimmune indications and operating at a similar development stage.
- Immunic Therapeutics: Clinical-stage biopharmaceutical company developing oral therapies for chronic inflammatory and autoimmune diseases. Comparable as a similarly-sized clinical-stage company targeting autoimmune indications with similar binary risk profile.
- Caballeta Bio: Clinical-stage biotechnology company developing cell therapies for autoimmune diseases. Comparable in focus area and development stage, though with a more specialized cell therapy modality versus Kinevant's broader approach.
- Arcturus Therapeutics: Clinical-stage biotechnology company developing therapeutics for rare diseases including autoimmune indications. Comparable as a similarly-sized emerging player in the rare autoimmune space with similar development-stage risk profile.
Direct peers
- Immunovant: Sister Vant under Roivant Sciences focused on autoimmune diseases. Most directly comparable as it shares the same platform model, parent company, and therapeutic focus area, but operates at a more advanced stage with publicly disclosed clinical assets.
- Chemocentryx: Biopharmaceutical company focused on autoimmune and inflammatory diseases (acquired by Amgen in 2022). Comparable as a company that successfully developed and commercialized rare autoimmune disease therapeutics, illustrating a potential exit pathway for Kinevant.
- Priovant Therapeutics: Sister Vant under Roivant Sciences developing targeted therapies for severe autoimmune disease. Shares the same operational model, parent backing, and therapeutic focus, making it the closest comparable in terms of organizational structure and strategic intent.
- Provention Bio: Biopharmaceutical company focused on autoimmune diseases, particularly type 1 diabetes (acquired by Sanofi in 2023). Comparable as a rare autoimmune disease developer that achieved successful commercialization and exit, relevant precedent for Kinevant's trajectory.
Broad incumbents
- AbbVie: Major pharmaceutical company with significant autoimmune disease franchise including HUMIRA and SKYRIZI. Relevant as a potential acquirer and benchmark for commercial scale in autoimmune therapeutics that Kinevant could eventually partner with or be acquired by.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Kinevant Sciences social profiles
Digital presenceKinevant Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kinevant Sciences leadership team
Management profileNumber of profiles
Profiles1 record
Kinevant Sciences funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kinevant Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kinevant Sciences
What does Kinevant Sciences do?
Kinevant Sciences is a clinical-stage biopharmaceutical company developing therapeutics for rare autoimmune diseases with significant unmet medical needs. As a subsidiary "Vant" under Roivant Sciences, it focuses its pipeline on rare autoimmune indications, leveraging Roivant's technology-enabled discovery, development, and commercialization capabilities. The company is currently pre-commercial and operates with 1-10 employees.
When was Kinevant Sciences founded?
Kinevant Sciences was founded in 2019. It employs 1 to 10 people.
Where is Kinevant Sciences based?
Kinevant Sciences is headquartered in New York, United States, in the North America region.
Who are Kinevant Sciences's main competitors?
Emerging players on record are AnaptysBio, Viridian Therapeutics, Immunic Therapeutics, Caballeta Bio and Arcturus Therapeutics. Direct peers are Immunovant, Chemocentryx, Priovant Therapeutics and Provention Bio. AbbVie is listed as a broad incumbent.
Does Kinevant Sciences have an API?
No public API is recorded for Kinevant Sciences.
What industry is Kinevant Sciences in?
Kinevant Sciences's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.